Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2363049 Target Snapshot

Epidermal growth factor receptor · PROTEIN FAMILY · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
157Compounds
53Assays
1Approved Drugs
97.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Epidermal growth factor receptor shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P04626. Start with neoplasm, then reuse UniProt P04626 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with neoplasm, then reuse UniProt P04626 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 3 linked drugs
Open source guide
Disease program
neoplasm

Epidermal growth factor receptor shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 3 linked drugs remain visible in the same block.

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include KBP5209, POZIOTINIB, VANDETANIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 3 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Epidermal growth factor receptor as ChEMBL target CHEMBL2363049, mapped to UniProt P04626. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Epidermal growth factor receptor
PROTEIN FAMILY · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2363049
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P04626
Receptor tyrosine-protein kinase erbB-2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Epidermal growth factor receptor is the right protein anchor across sources, using UniProt P04626 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why neoplasm is currently framed as approved-linked support. It currently carries 3 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameEpidermal growth factor receptor
Target TypePROTEIN FAMILY
OrganismHomo sapiens
UniProtP04626
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelReceptor tyrosine-protein kinase erbB-2
UniProt AccessionP04626
Component TypeProtein
Sequence Length1255 aa

Receptor tyrosine-protein kinase erbB-2

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Epidermal growth factor receptor, mapped to UniProt P04626. ChEMBL maps the protein component as Receptor tyrosine-protein kinase erbB-2. Sequence length is 1255 aa.

Mapped IDP04626
Review nameEpidermal growth factor receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Epidermal growth factor receptor shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
neoplasm
3 linked drugs · 3 direct · 3 efficacy
Linked drugKBP5209
Linked drugPOZIOTINIB
Linked drugVANDETANIB
Approved-linked Approved
cancer
2 linked drugs · 2 direct · 2 efficacy
Linked drugPOZIOTINIB
Linked drugVANDETANIB
Approved-linked Approved
medullary thyroid gland carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugVANDETANIB
Approved-linked Approved
papillary thyroid carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugVANDETANIB
Approved-linked Approved
thyroid cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugVANDETANIB
Approved-linked Approved
thyroid carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugVANDETANIB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include KBP5209, POZIOTINIB, VANDETANIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseneoplasm
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Approved
1
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC5095.0
EC502.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL2387001 9.16 IC50 0.69 Preclinical
CHEMBL2387000 9.05 IC50 0.89 Preclinical
CHEMBL2386999 8.92 IC50 1.2 Preclinical
CHEMBL3622673 8.77 IC50 1.7 Preclinical
CHEMBL587723 8.7 IC50 2.0 Clinical
CHEMBL3086102 8.52 IC50 3.0 Preclinical
CHEMBL4650319 8.48 IC50 3.3 Approved
CHEMBL2386998 8.34 IC50 4.6 Preclinical
CHEMBL3956925 8.3 IC50 5.0 Preclinical
CHEMBL3985592 8.3 IC50 5.0 Preclinical
Distribution

pChEMBL Value Distribution

1
5.0
9
5.5
10
6.0
16
6.5
20
7.0
11
7.5
10
8.0
4
8.5
2
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

MOBOCERTINIB
CHEMBL4650319
Approved 2021
Properties Compare Identifier
Assay Landscape

Assay Landscape

53
Total Assays
83
Tested Compounds
1
Assay Types
Binding — 53 assays, 83 compounds
BAO Format Assays Compounds Avg pChEMBL
protein format 38 33 6.8
cell-based format 14 50 7.4
assay format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine